#China #Suzhou #biopharmaceuticals #ADC Development #BioDlink

Recognition for Innovation in Biopharma

In a significant achievement, BioDlink, an innovative Contract Development and Manufacturing Organization (CDMO), was awarded the prestigious title of 'Emerging CDMO of the Year' at the Asia-Pacific Biopharma Excellence Awards, organized by IMAPAC. This recognition, announced on March 13, 2026, highlights BioDlink's pivotal role in revolutionizing biopharmaceutical development, particularly in the fields of complex biologics and antibody-drug conjugates (ADCs).

Celebrating Industry Excellence

The Asia-Pacific Biopharma Excellence Awards celebrate organizations in the biopharmaceutical industry that excel in technological capabilities, operational excellence, and leadership. By recognizing these achievements, the awards underscore the companies that are influential in shaping the future landscape of global biopharma.

BioDlink's designation is a testament to its commitment to delivering integrated solutions that support various stages of drug development, from early research and technology evaluation to comprehensive process and analytical development, culminating in efficient manufacturing.

Innovative Technology Platforms

At the heart of BioDlink's impressive capabilities are its proprietary technology platforms, crafted to enhance both development efficiency and scalability. Notably, the GL-DisacLink® platform simplifies ADC manufacturing via a streamlined, enzyme-based conjugation strategy. Another key innovation, BDKcell™, supports high-expression performance in standard fed-batch processes across several biologic modalities, including monoclonal antibodies and fusion proteins. The BDKLyo digital-intelligent lyophilization process calculation platform leverages predictive modeling to propel development speed and facilitate effective scale-up, ensuring that partners reach critical production milestones expeditiously and reliably.

Commitment to Quality

Quality is foundational to BioDlink's operations. The company adheres to a robust quality management system that aligns with international regulatory standards. Having successfully undergone more than 100 client and regulatory audits, BioDlink ensures consistent manufacturing quality and readiness for global market entry. This meticulous focus on quality continues to solidify its reputation as a trusted partner in the biopharmaceutical arena.

Expanding Capabilities to Meet Global Demand

With the global demand for advanced biologics and ADCs on the rise, BioDlink is dedicated to reinforcing its technology platforms and expanding its manufacturing capacities. The company seeks to deepen collaborations within the biopharmaceutical ecosystem, thus accelerating the delivery of innovative therapies to patients worldwide. BioDlink pledges to embody its philosophy of 'Quality First, Innovation Driven, Success Together' as it strives to enhance global access to next-generation biologics.

About BioDlink

Headquartered in Suzhou, China, BioDlink (stock symbol: 1875.HK) is a leading CDMO specializing in biologics and bioconjugates like ADCs. With additional centers in Shanghai and Beijing, the company offers fully integrated services from early research and development to commercial manufacturing. Its unique integrated platform, underpinned by proprietary technologies, enables partners to accelerate development processes while minimizing costs. BioDlink operates four commercial manufacturing lines with sterile fill-finish capabilities that comply with global GMP standards. Their quality management system, recognized by PMDA accreditation in Japan, facilitates product approvals across diverse international markets, including China, Indonesia, and Nigeria, among others.

For more information about BioDlink's innovative solutions and services, please visit their official website.